日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study

在健康受试者中，H4R抑制剂伊祖福兰的药代动力学、药效学和安全性：一项I期单次和多次递增剂量研究

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.70032
Jin, Byung Hak; Hong, Taegon; Yoo, Byung Won; Kim, Choon Ok; Kim, Dasohm; Kim, Youn Nam; Park, Min Soo
发表日期：2024
文献求助 收藏

Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers

健康男性志愿者中依格列汀与恩格列净或达格列净的药代动力学和药效学药物相互作用

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13566
Kim, Dasohm; Choi, Minkyu; Jin, Byung Hak; Hong, Taegon; Kim, Choon Ok; Yoo, Byung Won; Park, Min Soo
发表日期：2023
文献求助 收藏

Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects

在健康受试者中评估洛贝格列酮、恩格列净和二甲双胍之间的药代动力学相互作用

期刊:Translational and Clinical Pharmacology
影响因子:1.5
doi:10.12793/tcp.2023.31.e4
Kim, Heeyoung; Kim, Choon Ok; Park, Hyeonsoo; Park, Min Soo; Kim, Dasohm; Hong, Taegon; Shin, Yesong; Jin, Byung Hak
发表日期：2023
文献求助 收藏

Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects

在健康受试者中评估阿莫西林、克拉霉素和钾竞争性酸阻滞剂YH4808之间的药代动力学相互作用

期刊:Translational and Clinical Pharmacology
影响因子:1.5
doi:10.12793/tcp.2020.28.e5
Lee, Woo Yul; Oh, EunSil; Cui, Mengqi; Kim, Choon Ok; Lim, Yeji; Kim, Hunam; Park, Hyeonsoo; Yoon, Sukyong; Park, Min Soo; Hong, Taegon
发表日期：2020
文献求助 收藏

Comparison of the Pharmacokinetic-Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers.

比较两种达贝泊汀α制剂在健康男性志愿者中的药代动力学-药效学关系

期刊:BioDrugs
影响因子:6.9
doi:10.1007/s40259-018-0323-0
Kim Seokuee, Hong Taegon, Ko Jae-Wook, Huh Wooseong, Kim Jung-Ryul
其它
发表日期：2019
文献求助 收藏

The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male

在健康成年男性中，含埃索美拉唑 20 mg/碳酸氢钠 800 mg 的速释制剂的安全性、药效学和药代动力学研究

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S212491
Kim, Dasohm; Park, Min Soo; Yoo, Byung Won; Hong, Taegon; Park, Shin Jung; Kim, Choon Ok
发表日期：2019
文献求助 收藏

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers

生物类似药非格司亭与参比制剂的比较：健康志愿者中的药代动力学、药效学和安全性分析

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S158277
Choi, Chungam; Yoo, Byung Won; Kim, Choon Ok; Hong, Taegon; Jin, Byung Hak; Seo, Kwang-Seok; Jang, Ja Yun; Park, Min Soo
发表日期：2018
文献求助 收藏

Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans

基于生理的药代动力学预测韩国人肠道BCRP介导的瑞舒伐他汀药物相互作用

期刊:Korean Journal of Physiology & Pharmacology
影响因子:2.2
doi:10.4196/kjpp.2018.22.3.321
Bae, Soo Hyeon; Park, Wan-Su; Han, Seunghoon; Park, Gab-Jin; Lee, Jongtae; Hong, Taegon; Jeon, Sangil; Yim, Dong-Seok
BCR
CRP
发表日期：2018
文献求助 收藏

Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysis

采用混合效应分析法量化了非马沙坦在肝硬化中的疗效降低。

期刊:Translational and Clinical Pharmacology
影响因子:1.5
doi:10.12793/tcp.2017.25.1.43
Kim, Choon Ok; Jeon, Sangil; Han, Seunghoon; Hong, Taegon; Park, Min Soo; Yoon, Young-Ran; Yim, Dong-Seok
肝硬化
发表日期：2017
文献求助 收藏

Pharmacokinetic drug interaction between atorvastatin and ezetimibe in healthy Korean volunteers

阿托伐他汀与依折麦布在健康韩国志愿者中的药代动力学药物相互作用

期刊:Translational and Clinical Pharmacology
影响因子:1.5
doi:10.12793/tcp.2017.25.4.202
Park, Jungsin; Kim, Choon Ok; Jin, Byung Hak; Yang, Seoungwon; Park, Min Soo; Hong, Taegon
发表日期：2017
文献求助 收藏